Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 4,671 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions: bosentan; Drug
Lead sponsor: Rajan Saggar; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Hypertension, Pulmonary
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Vorolanib, Atezolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Embolism and Thrombosis
Interventions: EkoSonic Endovascular System with thrombolytic; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 65
States / cities: Glendale, Arizona • Los Angeles, California • Englewood, Colorado + 54 more

Conditions: Asthma
Interventions: MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Budesonide inhalation suspension 0.5mg; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions: Study Drug Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Days to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Interventions: 4D Computed Tomography (CT), Cone Beam CT, Low-dose Cinefluorography, Pulmonary Function Tests; Radiation · Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS-CoV-2
Interventions: REGN14256, imdevimab, casirivimab + imdevimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 28
States / cities: La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Continuous positive airway pressure (CPAP), Mask exhaust port flow; Device · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: ZD6474 (vandetanib), Best Supportive Care; Drug · Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Tucson, Arizona • Germantown, Tennessee

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Conditions: Asthma
Interventions: OMT, Light touch; Procedure · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Mayfield Heights, Ohio

Conditions: Rhinitis
Interventions: montelukast, placebo; Drug
Lead sponsor: Bernstein, Jonathan A., M.D.; Individual
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Cancer
Interventions: HPPH; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
Interventions: L-alanosine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 12
States / cities: Birmingham, Alabama • Tucson, Arizona • La Verne, California + 7 more

Conditions: Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Pulmonary Embolism, Splanchnic Vein Thrombosis
Interventions: Apixaban; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 32
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more

Conditions: Hypertension, Pulmonary
Interventions: sildenafil, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 24
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
U.S. locations: 34
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Interventions: PF-06936308; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 34
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 17 more

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: 3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis; Radiation · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: Intensity Modulated Radiation Therapy, 3-Dimensional Conformal Radiation Therapy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors
Interventions: BAY2416964, Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Ramelteon and Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more

Conditions: Deglutition Disorders, Mechanical Ventilation Complication, Complication of Ventilation Therapy
Interventions: Exercise and sensory stimulation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

An International Pulmonary Embolism Registry Using EKOS

A Study of 2 Doses of MAP0010 in Adult Asthmatics

Trial of Reducing Inpatient Antibiotic Durations in Children

Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

Assessment of Circuit Rebreathing During CPAP Therapy

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Asthma and Osteopathic Manipulative Technique

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Alanosine in Treating Patients With Cancer

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

PReventing the EffectS of Intubation on DEglutition